Lung cancer circulating biomarkers
Research type
Research Study
Full title
A study of lung cancer circulating biomarkers.
IRAS ID
135480
Contact name
Phil Crosbie
Contact email
Sponsor organisation
University Hospital of South Manchester NHS Foundation Trust
Research summary
In the UK, lung cancer is responsible for one in five of all cancer deaths and has one of the poorest prognoses of all malignant diseases with 75% of patients dying within the first year and less than 10% surviving for five years. This is attributed to the late clinical presentation of the majority of patients; 80% present with locally advanced or metastatic disease. The National Lung Screening Trial (NLST) showed for the first time a significant reduction (20%) in lung cancer specific mortality by screening asymptomatic at risk patients with low dose CT. The limitation of radiological screening was the very high rate of false positive scans, in the order of 95% in the NLST. The development of a biomarker that could identify disease or increased susceptibility to disease would be a valuable adjunct by enabling identification of early stage lung cancer or stratification of at risk individuals/populations. This would have the potential to focus screening strategies and allow earlier diagnosis with a consequent improvement in treatment outcomes.
Previously we performed a case-control study at UHSM examining differences in certain blood borne markers (DNA damage and repair) and genotype to look for differences between patients with and without lung cancer. We would like to expand this study to look at additional blood borne markers in the same patient cohort.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
13/NW/0538
Date of REC Opinion
10 Jul 2013
REC opinion
Favourable Opinion